XML 55 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8
Other Expense
 3 Months Ended
Mar. 31, 2014
Other Income and Expenses [Abstract]  
Other expense
Other expense consists of:

 
Three Months Ended
March 31,
($ in millions)
2014
 
2013
Development income
$
(0.4
)
 
$
(0.3
)
Acquisition-related contingencies
0.4

 
—

Foreign exchange and other
0.7

 
0.5

 
$
0.7

 
$
0.2



During the three months ended March 31, 2014, we recognized $0.4 million of development income within our Pharmaceutical Delivery Systems segment ("Delivery Systems") related to a nonrefundable customer payment received in 2013 for the exclusive use of SmartDose within a specific therapeutic area. As of March 31, 2014, there was $18.6 million of unearned income related to this payment, of which $1.5 million was included in other current liabilities and $17.1 million was included in other long-term liabilities. The unearned income is being recognized as development income on a straight-line basis over the remaining term of the agreement. The agreement does not include a future minimum purchase commitment from the customer. During the three months ended March 31, 2013, we recorded development income of $0.3 million within Delivery Systems.

During the three months ended March 31, 2014, the SmartDose contingent consideration increased by $0.4 million, due to the time value of money and adjustments related to changes in sales projections. The change in the SmartDose contingent consideration during the three months ended March 31, 2013 was immaterial.